Growth Hormone Therapy.
10.5124/jkma.2002.45.2.206
- Author:
Sung Woon KIM
- Publication Type:Original Article
- Keywords:
Growth hormone;
Replacement therapy;
Abdominal obesity syndrome;
Osteoporosis;
Quality of life
- MeSH:
Adipose Tissue;
Adult;
Biomarkers;
Growth Hormone*;
Humans;
Insulin-Like Growth Factor I;
Muscles;
Osteoporosis;
Pituitary Diseases;
Quality of Life
- From:Journal of the Korean Medical Association
2002;45(2):206-215
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
The safe clinical practice of growth hormone(GH) replacement requires judgement of the overall GH status, however, there is no biological marker for this in adults. In addition, diverse actions of GH in healthy individuals render the assessment of optimal GH replacement difficult. As in other fields of clinical practice, strategies and protocols vary between centers, however, most physicians experienced in pituitary diseases agree that GH replacement should begin at low doses, and increased to the final maintenance dose. The adequacy replacement is best determined by combination of clinical response and serum IGF-I, level avoiding supraphysiological levels of this GH-dependent peptide. Actually, GH can reduce body fat and restore muscles, bones, and quality of life. Appropriate using of GH will elicit antiaging effects.
